肥胖不改变胱抑素C相关eGFR与肾脏及心血管结局的关联
该队列研究纳入27249名美国成年人,评估腰围或BMI是否改变基于胱抑素C的eGFR(eGFRcys)与全因死亡、肾衰竭、动脉粥样硬化性心血管疾病(ASCVD)及心衰的关联。结果显示,eGFRcys每降低15mL/min/1.73m2,各腰围四分位组及各BMI分类内死亡风险均升高,且腰围和BMI均未显著改变eGFRcys与上述4种结局的关联(所有交互P>0.05)。
要点
- 在腰围各四分位组及BMI各分类内,eGFRcys每降低15mL/min/1.73m2与全因死亡风险升高相关。
- 腰围和BMI均未显著改变eGFRcys与死亡、肾衰竭、ASCVD或心衰的关联(所有交互P>0.05)。
- 在肥胖个体中,胱抑素C可用于提供基于eGFR的不良结局风险预测。
核心结论
- 肥胖未改变eGFRcys与全因死亡、肾衰竭、新发ASCVD或新发心衰的关联。
- 在肥胖个体中,胱抑素C可用于提供基于eGFR的不良结局风险预测。
研究设计与样本
- 研究为队列研究,纳入美国REGARDS研究中的27249名成年人。
主要发现
- 参与者平均年龄65岁,54%为女性,41%为黑人,21%的eGFRcys<60mL/min/1.73m2。
- 基线腹型肥胖(女性腰围≥88cm或男性≥102cm)患病率为48%,肥胖患病率为38%。
- 多变量校正后,eGFRcys每降低15mL/min/1.73m2,各腰围四分位组死亡HR分别为:第一四分位1.19(1.15-1.24),第二四分位1.22(1.18-1.26),第三四分位1.20(1.16-1.24),第四四分位1.19(1.15-1.23)。
- eGFRcys每降低15mL/min/1.73m2,各BMI分类死亡HR分别为:BMI<24.9为1.21(1.17-1.25),BMI 25.0-29.9为1.21(1.18-1.25),BMI 30.0-34.9为1.20(1.16-1.25),BMI≥35为1.17(1.12-1.22)。
- 腰围和BMI均未改变eGFRcys与死亡、肾衰竭、新发ASCVD或新发心衰的关联(所有交互P>0.05)。
关键数值与推荐
- 腹型肥胖定义为腰围≥88cm(女性)或≥102cm(男性)。
- 肥胖分类依据BMI:<24.9、25.0-29.9、30.0-34.9、≥35。
临床怎么用
- 在肥胖个体中,胱抑素C可用于提供基于eGFR的不良结局风险预测。
局限性
- 研究仅纳入美国黑人和白人。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Cystatin C-based estimated glomerular filtration rate (eGFRcys) has stronger associations with adverse clinical outcomes than creatinine-based eGFR (eGFRcr). Obesity may be associated with higher cystatin C levels, independent of kidney function, but it is unknown whether obesity modifies associations of eGFRcys with kidney and cardiovascular outcomes. STUDY DESIGN: Cohort study. SETTING & PARTICIPANTS: 27,249 US adults in the Reasons for Geographic and Racial Differences in Stroke Study. PREDICTORS: eGFRcys, eGFRcr, waist circumference, and body mass index (BMI). OUTCOME: All-cause mortality, kidney failure, incident atherosclerotic cardiovascular disease (ASCVD), and incident heart failure (HF). ANALYTICAL APPROACH: Multivariable Cox and Fine-Gray models with multiplicative interaction terms were constructed to investigate whether waist circumference quartiles or BMI categories modified associations of eGFRcys with risks of 4 clinical outcomes. RESULTS: Participants had a mean age of 65 years; 54% were women, 41% were Black, and 21% had an eGFRcys<60mL/min/1.73m2. The baseline prevalence of abdominal obesity (waist circumference≥88cm for women or≥102cm for men) was 48% and obesity was 38%. In multivariable adjusted analyses, each 15mL/min/1.73m2 lower eGFRcys was associated with higher HR and 95% CI of mortality in each waist circumference quartile (first quartile, 1.19 [1.15-1.24]; second quartile, 1.22 [1.18-1.26]; third quartile, 1.20 [1.16-1.24]; fourth quartile, 1.19 [1.15-1.23]) as well as within each BMI category (BMI<24.9: 1.21 [1.17-1.25]; BMI 25.0-29.9: 1.21 [1.18-1.25]; BMI 30.0-34.9: 1.20 [1.16-1.25]; BMI≥35: 1.17, [1.12-1.22]). Neither waist circumference nor BMI modified the association of eGFRcys with mortality, kidney failure, incident ASCVD, or incident HF (all Pinteraction>0.05). LIMITATIONS: Included only Black and White persons in the United States. CONCLUSION: Obesity did not modify the association of eGFRcys with all-cause mortality, kidney failure, incident ASCVD, or incident HF. Among individuals with obesity, cystatin C may be used to provide eGFR-based risk prognostication for adverse outcomes. PLAIN-LANGUAGE SUMMARY: Cystatin C is increasingly used in clinical practice to estimate kidney function, and cystatin C-based eGFR (eGFRcys) may be used to determine risk for adverse clinical outcomes. Adiposity may increase serum levels of cystatin C, independent of kidney function. This cohort study investigated whether associations of eGFRcys with adverse kidney and cardiovascular outcomes are modified by measures of obesity, waist circumference, and body mass index. We found that obesity does not modify associations of eGFRcys with 4 clinical outcomes and conclude that among individuals with obesity, cystatin C may be used to provide eGFR-based risk prognostication for adverse outcomes.
引用
- Chen DC, Scherzer R, Ix JH, et al. Modification of Association of Cystatin C With Kidney and Cardiovascular Outcomes by Obesity. Am J Kidney Dis. 2023. PMID: 37866793. doi:10.1053/j.ajkd.2023.08.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。